X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/ucb-presents-new-data-highlighting-developments-across-expansive-neurology-portfolio-at-76th-american-academy-of-neurology-aan-annual-meeting-302114927.html
https://www.prnewswire.com/news-releases/fda-accepts-supplemental-biologics-license-applications-for-bimzelx-bimekizumab-bkzx-for-moderate-to-severe-hidradenitis-suppurativa-and-additional-2ml-device-presentations-302107800.html
https://endpts.com/ucb-debuts-first-campaign-for-psoriasis-drug-bimzelx-during-oscars/
https://www.prnewswire.com/news-releases/pantherx-rare-selected-by-ucb-as-the-exclusive-specialty-pharmacy-for-zilbrysq-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-gmg-in-adult-patients-who-are-anti-acetylcholine-receptor-achr-antibody-positive-302031436.html
https://endpts.com/ucb-departs-industry-trade-group-bio-following-pfizers-exit-late-last-year/
https://www.prnewswire.com/news-releases/zilbrysq-zilucoplan-is-now-commercially-available-in-the-us-for-the-treatment-of-generalized-myasthenia-gravis-gmg-in-adult-patients-who-are-anti-acetylcholine-receptor-achr-antibody-positive-302025019.html
https://www.prnewswire.com/news-releases/ucb-presents-new-data-about-the-real-world-experience-of-fintepla-fenfluramine-and-rare-epilepsy-syndromes-at-2023-american-epilepsy-society-aes-annual-meeting-302002158.html
https://www.prnewswire.com/news-releases/ucb-announces-us-availability-of-bimzelx-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis-301986731.html
https://www.prnewswire.com/news-releases/post-hoc-analysis-showed-cimzia-certolizumab-pegol-resulted-in-meaningful-efficacy-for-ra-patients-with-high-levels-of-rheumatoid-factor-rf-301985174.html
https://www.prnewswire.com/news-releases/ucb-presents-new-five-year-data-on-bimzelx-bimekizumab-bkzx-in-ankylosing-spondylitis-at-acr-convergence-2023-301984145.html
Market Place
Share 
